Dwyer Donald bought 15,000 shares of Vivani Medical, Inc. at $1.03 for $15.5k on Nov 12, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Chief Business Officer
Chief Business Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$15,495Shares × reported price
Shares traded
15,000Common Stock
Price per share
$1.03Reported price. Read footnotes for ranges.
% of reported position traded
25%This security and ownership context
Holdings after
75,000Direct
Trade date
Nov 12, 2026Buy
Filed
Nov 13, 2026, 9:32 PM ET2-day reporting delay
Accession
0001753926-26-002139Code P · Transaction 401604
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 60,000 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Buy5,000$0.83$4,150Trade 401603
2 transaction rows in this filing. Joint filers share the same rows.

VANI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VANI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 21, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +17%1w ago +3%1d ago +11%
Returns since7d30d90d180d1y

Footnotes in full

F1: Individual purchased shares on the open market. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.03 to $1.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.